The microbiology department at a North London hospital audited notifications of suspected meningococcal disease in response to a reported high rate, which it suspected was due to over-reporting out of hours to public health specialists. All cases notified over a 14-month period were assessed with regards to time of reporting and subsequent microbiological confirmation. Of 36 notifications, 18 were confirmed as bacterial, mostly meningococcal meningitis. Of the four types of sample readily obtainable on admission (blood culture, ethylene diamine tetra-acetic acid [EDTA] blood sample, throat swab and acute serum) all were obtained in only two cases. The reporting was considered appropriate, reflecting the relatively high incidence of meningococcal disease (MD) within the local population. Further cases might perhaps have been laboratory confirmed had all samples been sent on admission. A single form requesting all four samples in suspected meningococcal disease cases is recommended. Informing public health specialists out of hours could be rationalised.

Download full-text PDF

Source

Publication Analysis

Top Keywords

meningococcal disease
16
north london
8
suspected meningococcal
8
public health
8
health specialists
8
meningococcal
5
audit detection
4
detection notification
4
notification meningococcal
4
disease
4

Similar Publications

Long-term 4CMenB Vaccine Effectiveness Against Gonococcal Infection at Four Years Post-Program Implementation: Observational Case-Control Study.

Open Forum Infect Dis

January 2025

Vaccinology and Immunology Research Trials Unit, Women's and Children's Health Network, Adelaide, South Australia, Australia.

Background: A 4-component meningococcal B (4CMenB) vaccine program was introduced in adolescents in 2019 in South Australia. We aimed to evaluate long-term vaccine effectiveness (VE) and impact (VI) on gonococcal infection 4 years after implementation of the program.

Methods: Disease notification data were provided by SA Health.

View Article and Find Full Text PDF

To investigate the safety of the tetravalent meningococcal conjugate vaccine (MPCV-ACYW) in combination with the inactivated poliomyelitis (IPV) vaccine and diphtheria-tetanus-acellular pertussis (DTaP) vaccine for infants aged 3-5 months and provide real-world evidence for the immunization strategy of vaccine combination. From June to October 2023, a total of 600 3-month-old infants were selected and divided into three groups: control group, mono-vaccination group and combined vaccination group. They were simultaneously or individually vaccinated with MPCV-ACYW, IPV and DTaP vaccines at 3, 4, and 5 months of age, respectively.

View Article and Find Full Text PDF

October 2024 ACIP Meeting Update: Influenza, COVID-19, RSV and Other Vaccines.

Pediatrics

January 2025

Department of Pediatrics, University of Cincinnati College of Medicine and Division of Pediatric Infectious Diseases, Cincinnati Children's Hospital Medical Center, Cincinnati OH.

The Advisory Committee on Immunization Practices (ACIP), a group of medical and public health experts that provides advice to the Centers for Disease Control and Prevention, normally meets 3 times per year to develop US vaccine recommendations. The ACIP met October 23-24, 2024, to discuss influenza vaccines, chikungunya vaccines, coronavirus disease (COVID-19) vaccines, RSV immunizations, meningococcal vaccines, human papillomavirus (HPV) vaccines, pneumococcal vaccines, and adult and child/adolescent immunization schedule revisions. This update summarizes the proceedings of these meetings, with an emphasis on topics that are most relevant to the pediatric population.

View Article and Find Full Text PDF

The AEP 2025 Vaccination and Immunization Schedule recommended for children, adolescents and pregnant women residing in Spain features the following novelties: Due to the increase in measles cases and outbreaks in recent years, we recommend advancing the second dose of measles, mumps and rubella (MMR) vaccine to 2 years of age. As a consequence of the above, since many autonomous communities (ACs) use the quadrivalent vaccine for the second dose of MMR and varicella vaccines, we recommend, for all ACs, advancing the second dose of varicella vaccine to 2 years of age. Due to the very significant increase in cases of pertussis since late 2023 and especially in 2024, we recommend advancing the dose of Tdap given in adolescence to 10-12 years of age.

View Article and Find Full Text PDF

Erratum: Meningococcal Surveillance Australia: Reporting period 1 April to 30 June 2024.

Commun Dis Intell (2018)

January 2025

World Health Organisation Collaborating Centre for STI and AMR, Sydney and Neisseria Reference Laboratory, Department of Microbiology, NSW Health Pathology, The Prince of Wales Hospital, Randwick, 2031, NSW Australia.

Erratum to 2024;48. (doi: 10.33321/cdi.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!